Get the Stockscreener App
11.12
6.82%
0.71
Delcath Systems Inc stock is traded at $11.12, with a volume of 771.94K.
It is up +6.82% in the last 24 hours and up +0.36% over the past month.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
See More
Previous Close:
$10.41
Open:
$10.43
24h Volume:
771.94K
Relative Volume:
1.04
Market Cap:
$388.99M
Revenue:
$2.07M
Net Income/Loss:
$-47.68M
P/E Ratio:
-3.9433
EPS:
-2.82
Net Cash Flow:
$-31.31M
1W Performance:
+7.34%
1M Performance:
+0.36%
6M Performance:
-25.27%
1Y Performance:
+41.30%
1-Day Range:
$10.43
$11.25
1-Week Range:
$10.06
$11.25
52-Week Range:
$7.85
$18.23
Delcath Systems Inc Stock (DCTH) Company Profile
Name
Delcath Systems Inc
Sector
Industry
Phone
(518) 743-8892
Address
566 QUEENSBURY AVENUE, QUEENSBURY, NY
Compare DCTH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DCTH
Delcath Systems Inc
|
11.12 | 372.55M | 2.07M | -47.68M | -31.31M | -2.82 |
|
ABT
Abbott Laboratories
|
132.59 | 226.73B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.17 | 152.69B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
394.22 | 145.89B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.71 | 118.91B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
81.83 | 45.97B | 5.69B | 1.41B | 577.90M | 6.95 |
Delcath Systems Inc Stock (DCTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-28-24 | Initiated | Craig Hallum | Buy |
| May-14-24 | Initiated | Stephens | Overweight |
| Jul-26-22 | Resumed | Canaccord Genuity | Buy |
| Dec-10-21 | Initiated | H.C. Wainwright | Buy |
| Mar-09-21 | Initiated | Canaccord Genuity | Buy |
| Jan-05-21 | Initiated | BTIG Research | Buy |
| Jun-01-20 | Initiated | Laidlaw | Buy |
View All
Delcath Systems Inc Stock (DCTH) Latest News
Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer - BioSpace
First patient dosed in Delcath’s phase 2 trial for colorectal cancer - Investing.com
Heatmap Data Shows High Activity in Delcath Systems Inc. SectorWeekly Profit Summary & Daily Market Momentum Tracking - 선데이타임즈
Delcath Systems, Inc. (NASDAQ:DCTH) Q2 2025 Earnings Call Transcript - MSN
Delcath Systems Updates Bylaws for Governance Efficiency - MSN
Are Bears Losing Grip on Delcath Systems Inc.July 2025 Action & Growth-Oriented Investment Plans - sisaissue.com
Analyzing drawdowns of Delcath Systems Inc. with statistical toolsWeekly Gains Summary & Step-by-Step Swing Trade Plans - Newser
What’s next for Delcath Systems Inc. stock priceProduct Launch & Safe Entry Zone Tips - Newser
Delcath Systems Inc. stock chart pattern explained2025 Investor Takeaways & Verified Momentum Stock Alerts - Newser
Will Delcath Systems Inc. bounce back from current supportPortfolio Risk Summary & Pattern Based Trade Signal System - Newser
H.C. Wainwright Remains Bullish on Delcath Systems (DCTH) - MSN
Best data tools to analyze Pfizer Inc. stock2025 Key Highlights & Entry Point Confirmation Alerts - Newser
What MACD and RSI say about Delcath Systems Inc.July 2025 Fed Impact & Growth Focused Entry Point Reports - Newser
Visual analytics tools that track Delcath Systems Inc. performanceQuarterly Portfolio Report & AI Enhanced Execution Alerts - Newser
Using fundamentals and technicals on Delcath Systems Inc.Inflation Watch & AI Forecasted Stock Moves - Newser
Is Delcath Systems Inc. reversing from oversold territoryTrade Analysis Report & Proven Capital Preservation Methods - Newser
Key resistance and support levels for Delcath Systems Inc.Market Trend Review & Weekly Hot Stock Watchlists - Newser
Delcath Systems Inc. Stock Performance After Earnings: Historical InsightsWeekly Profit Report & Verified Entry Point Detection - Newser
Using Bollinger Bands to evaluate Delcath Systems Inc.July 2025 Action & Fast Entry and Exit Trade Plans - Newser
What makes Delcath Systems Inc. stock price move sharply2025 Growth vs Value & Free Safe Entry Trade Signal Reports - newsyoung.net
Delcath Systems' Earnings May Not Reflect the Company's True Financial Health - AInvest
Impressive Earnings May Not Tell The Whole Story For Delcath Systems (NASDAQ:DCTH) - Yahoo Finance
Healthcare Analysts Bullish on SI-Bone, Delcath Systems, and Cardiol Therapeutics - AInvest
12 Best Medical Device Stocks to Buy According to Analysts - Insider Monkey
Delcath Systems: Huge Potential But With The Handbrake On For Now (NASDAQ:DCTH) - Seeking Alpha
Is Delcath Systems Inc. Starting a New UptrendROI Boosting Trade Opportunity Calendar Published - beatles.ru
Delcath Systems Q3 EPS Forecast Decreased by HC Wainwright - Defense World
Will a bounce in Delcath Systems Inc. offer an exitDay Trading Setup Forecast with Trend Model - Newser
Why Delcath Systems Inc. stock attracts strong analyst attentionDaily Trade Setup Forecast with Confidence - Newser
Real time scanner hits for Delcath Systems Inc. explainedBuy and Hold Position Summary Review - Newser
Intraday pattern recognizer results for Delcath Systems Inc.Free AI Trading Suggestions With Accuracy Focus - Newser
Is Delcath Systems Inc. a turnaround storyBlue Chip Bargain Alerts - thegnnews.com
Delcath Systems (NASDAQ:DCTH) Price Target Raised to $31.00 - Defense World
Analysts Set Expectations for Delcath Systems Q1 Earnings - Defense World
Delcath Systems (NASDAQ:DCTH) Rating Lowered to “Hold” at Wall Street Zen - Defense World
Delcath outlines 175% projected HEPZATO volume growth and targets up to 28 operational centers by year-end 2025 amid expanding clinical pipeline - MSN
Delcath Systems, Inc. Just Recorded A 200% EPS Beat: Here's What Analysts Are Forecasting Next - simplywall.st
Delcath Systems, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - uk.finance.yahoo.com
Delcath Systems, Inc. (DCTH) Surpasses Q2 Earnings and Revenue Estimates - MSN
Delcath Systems Reports Strong Q2 2025 Results - The Globe and Mail
Delcath Systems Reports Strong Q2 Growth Amid Challenges - The Globe and Mail
Delcath’s Revenue Jumps As Cancer Kit Sales Climb - Finimize
Delcath Systems 2025 Q2 Earnings Strong Performance as Net Income Surges 119.6% - AInvest
H.C. Wainwright Maintains Delcath Systems(DCTH.US) With Buy Rating, Raises Target Price to $31 - 富途牛牛
Delcath Systems’ HEPZATO Drives Strong Growth and Expansion, Justifying Buy Rating - TipRanks
Delcath Systems (DCTH) Sees Analyst Target Price Raised by HC Wa - GuruFocus
We Like These Underlying Return On Capital Trends At Delcath Systems (NASDAQ:DCTH) - uk.finance.yahoo.com
Delcath Systems Reports Second Quarter 2025 Results and Business Highlights - BioSpace
Delcath Systems shares rise 4.23% premarket after reporting Q2 earnings beat and revenue growth. - AInvest
Delcath (DCTH) Q2 Revenue Jumps 210% - AOL.com
Delcath Systems shares rise 4.14% after-hours after reporting Q2 earnings beat and net income of USD 2.7 million. - AInvest
Delcath Systems Inc Stock (DCTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Delcath Systems Inc Stock (DCTH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MICHEL GERARD J | CHIEF EXECUTIVE OFFICER |
Oct 22 '24 |
Option Exercise |
6.00 |
16,666 |
99,996 |
319,334 |
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):